Dept of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, Tongji University, School of Medicine, Shanghai, China.
Eur Respir J. 2012 Mar;39(3):597-603. doi: 10.1183/09031936.00072911. Epub 2011 Jul 7.
Mutations of the bone morphogenetic protein type II receptor (BMPR2) gene predispose to pulmonary arterial hypertension (PAH). 290 idiopathic (I)PAH patients and 15 heritable (H)PAH were screened to determine the spectrum and rate of BMPR2 mutations in a large Chinese patient group. Gene sequencing and multiplex ligation-dependent probe amplification (MLPA®) were used to detect sequence mutations and large rearrangements (RGTs). Total mutation rate was 14.5% (n = 42 out of 290) in Chinese IPAH patients, and 53.3% (n = 8 out of 15) in HPAH patients. RGT mutation rate was 3.1% (n = 7 out of 229) and represented 14% (n = 7 out of 50) of all identified mutations. 25 BMPR2 mutations were newly identified. Patients in this study were younger than other reported PAH subjects. BMPR2 mutation carriers were ~6 yrs younger at diagnosis than noncarriers (p = 0.002), but this relationship was significant only in the female group, which was larger. The proportion of females carrying a BMPR2 mutation was half that of males (12.8% versus 25.3%; p = 0.008). Our results indicate that the overall genetics of Chinese PAH patients is similar to that of other populations, but the clinical picture differs by the precocity of the disease in the whole patient group, and the lower proportion of females found to carry a BMPR2 mutation.
骨形成蛋白受体 2 型(BMPR2)基因突变可导致肺动脉高压(PAH)。对 290 例特发性(I)PAH 患者和 15 例遗传性(H)PAH 患者进行了筛选,以确定大型中国患者群体中 BMPR2 基因突变的谱和突变率。基因测序和多重连接依赖性探针扩增(MLPA®)用于检测序列突变和大片段重排(RGTs)。在中国 IPAH 患者中,总突变率为 14.5%(290 例中有 42 例),在 HPAH 患者中为 53.3%(15 例中有 8 例)。RGT 突变率为 3.1%(229 例中有 7 例),占所有鉴定出的突变的 14%(50 例中有 7 例)。新发现了 25 种 BMPR2 突变。本研究中的患者比其他报道的 PAH 患者年轻。BMPR2 突变携带者的诊断年龄比非携带者年轻约 6 岁(p=0.002),但这种关系仅在更大的女性组中显著。携带 BMPR2 突变的女性比例是男性的一半(12.8%比 25.3%;p=0.008)。我们的结果表明,中国 PAH 患者的总体遗传学与其他人群相似,但疾病的早熟性使整个患者群体的临床表现不同,而且发现携带 BMPR2 突变的女性比例较低。